Total Payments
$29,006
2024 Payments
$236.84
Companies
6
Transactions
25
Medicare Patients
639
Medicare Billing
$62,458
Payment Breakdown by Category
Consulting$16,332 (56.3%)
Travel$11,900 (41.0%)
Food & Beverage$538.13 (1.9%)
Other$236.84 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $16,332 | 8 | 56.3% |
| Travel and Lodging | $11,900 | 10 | 41.0% |
| Food and Beverage | $538.13 | 6 | 1.9% |
| Compensation for serving as faculty or as a speaker for a medical education program | $236.84 | 1 | 0.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $14,619 | 11 | $0 (2017) |
| Progenics Pharmaceuticals, Inc. | $6,049 | 7 | $0 (2023) |
| Merck Sharp & Dohme LLC | $4,688 | 4 | $0 (2023) |
| HRA Pharma Rare Diseases | $3,400 | 1 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $236.84 | 1 | $0 (2024) |
| Radius Health, Inc. | $13.54 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $236.84 | 1 | AstraZeneca Pharmaceuticals LP ($236.84) |
| 2023 | $4,265 | 4 | Progenics Pharmaceuticals, Inc. ($3,515) |
| 2022 | $2,374 | 2 | Progenics Pharmaceuticals, Inc. ($2,374) |
| 2021 | $937.50 | 1 | Merck Sharp & Dohme Corporation ($937.50) |
| 2020 | $6,422 | 4 | HRA Pharma Rare Diseases ($3,400) |
| 2019 | $137.51 | 1 | Progenics Pharmaceuticals, Inc. ($137.51) |
| 2018 | $13.54 | 1 | Radius Health, Inc. ($13.54) |
| 2017 | $14,619 | 11 | PFIZER INC. ($14,619) |
All Payment Transactions
25 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/31/2024 | AstraZeneca Pharmaceuticals LP | — | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $236.84 | General |
| 05/04/2023 | Progenics Pharmaceuticals, Inc. | AZEDRA (Drug) | Travel and Lodging | In-kind items and services | $1,594.36 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 05/04/2023 | Progenics Pharmaceuticals, Inc. | AZEDRA (Drug) | Food and Beverage | In-kind items and services | $49.00 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 04/06/2023 | Progenics Pharmaceuticals, Inc. | AZEDRA (Drug) | Consulting Fee | Cash or cash equivalent | $1,872.00 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 01/04/2023 | Merck Sharp & Dohme LLC | WELIREG (Drug) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: ONCOLOGY | ||||||
| 12/15/2022 | Progenics Pharmaceuticals, Inc. | AZEDRA (Drug) | Consulting Fee | Cash or cash equivalent | $1,872.00 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 12/15/2022 | Progenics Pharmaceuticals, Inc. | AZEDRA (Drug) | Travel and Lodging | In-kind items and services | $502.20 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 11/24/2021 | Merck Sharp & Dohme Corporation | WELIREG (Drug) | Consulting Fee | Cash or cash equivalent | $937.50 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2020 | Progenics Pharmaceuticals, Inc. | AZEDRA (Drug) | Food and Beverage | In-kind items and services | $21.79 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 11/06/2020 | Merck Sharp & Dohme Corporation | MK-6482 (Drug) | Consulting Fee | Cash or cash equivalent | $1,875.00 | General |
| Category: ONCOLOGY | ||||||
| 09/23/2020 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $1,125.00 | General |
| 07/13/2020 | HRA Pharma Rare Diseases | Lysodren (Drug) | Consulting Fee | Cash or cash equivalent | $3,400.00 | General |
| Category: Inoperable adrenal cortical carcinoma | ||||||
| 04/27/2019 | Progenics Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $137.51 | General |
| 10/11/2018 | Radius Health, Inc. | Tymlos (Biological) | Food and Beverage | In-kind items and services | $13.54 | General |
| Category: Endocrinology | ||||||
| 07/19/2017 | PFIZER INC. | SOMAVERT (Drug) | Travel and Lodging | In-kind items and services | $43.73 | General |
| Category: ENDOCRINE DISEASE;METABOLIC DISEASE | ||||||
| 06/12/2017 | PFIZER INC. | SOMAVERT (Drug) | Travel and Lodging | In-kind items and services | $450.03 | General |
| Category: ENDOCRINE DISEASE;METABOLIC DISEASE | ||||||
| 06/12/2017 | PFIZER INC. | SOMAVERT (Drug) | Food and Beverage | In-kind items and services | $240.51 | General |
| Category: ENDOCRINE DISEASE;METABOLIC DISEASE | ||||||
| 06/12/2017 | PFIZER INC. | SOMAVERT (Drug) | Travel and Lodging | In-kind items and services | $216.44 | General |
| Category: ENDOCRINE DISEASE;METABOLIC DISEASE | ||||||
| 06/12/2017 | PFIZER INC. | SOMAVERT (Drug) | Travel and Lodging | In-kind items and services | $163.23 | General |
| Category: ENDOCRINE DISEASE;METABOLIC DISEASE | ||||||
| 02/24/2017 | PFIZER INC. | SOMAVERT (Drug) | Consulting Fee | Cash or cash equivalent | $4,500.00 | General |
| Category: ENDOCRINE DISEASE;METABOLIC DISEASE | ||||||
| 02/16/2017 | PFIZER INC. | SOMAVERT (Drug) | Travel and Lodging | In-kind items and services | $92.19 | General |
| Category: ENDOCRINE DISEASE;METABOLIC DISEASE | ||||||
| 02/02/2017 | PFIZER INC. | SOMAVERT (Drug) | Travel and Lodging | In-kind items and services | $7,965.56 | General |
| Category: ENDOCRINE DISEASE;METABOLIC DISEASE | ||||||
| 02/02/2017 | PFIZER INC. | SOMAVERT (Drug) | Travel and Lodging | In-kind items and services | $467.33 | General |
| Category: ENDOCRINE DISEASE;METABOLIC DISEASE | ||||||
| 02/02/2017 | PFIZER INC. | SOMAVERT (Drug) | Travel and Lodging | In-kind items and services | $404.52 | General |
| Category: ENDOCRINE DISEASE;METABOLIC DISEASE | ||||||
| 02/02/2017 | PFIZER INC. | SOMAVERT (Drug) | Food and Beverage | In-kind items and services | $75.78 | General |
| Category: ENDOCRINE DISEASE;METABOLIC DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 123 | 148 | $81,974 | $15,363 |
| 2022 | 2 | 114 | 141 | $62,622 | $13,788 |
| 2021 | 7 | 231 | 278 | $88,889 | $22,502 |
| 2020 | 7 | 171 | 192 | $53,915 | $10,805 |
Total Patients
639
Total Services
759
Medicare Billing
$62,458
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 105 | 130 | $69,400 | $13,168 | 19.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 18 | 18 | $12,574 | $2,194 | 17.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 76 | 102 | $52,701 | $11,054 | 21.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 38 | 39 | $9,921 | $2,734 | 27.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 52 | 61 | $30,171 | $6,813 | 22.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 73 | 74 | $18,034 | $5,133 | 28.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 20 | 38 | $10,754 | $3,144 | 29.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 23 | 23 | $10,204 | $2,527 | 24.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 24 | 32 | $7,004 | $1,886 | 26.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 13 | 13 | $6,936 | $1,834 | 26.4% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 26 | 37 | $5,786 | $1,165 | 20.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 63 | 63 | $14,904 | $3,545 | 23.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 41 | 51 | $24,259 | $3,516 | 14.5% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2020 | 17 | 17 | $5,467 | $1,351 | 24.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 15 | 18 | $3,673 | $1,082 | 29.5% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 11 | 13 | $1,678 | $555.88 | 33.1% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 11 | 16 | $2,390 | $476.72 | 19.9% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Facility | 2020 | 13 | 14 | $1,544 | $279.50 | 18.1% |
About Dr. Camilo Jimenez, M.D
Dr. Camilo Jimenez, M.D is a Endocrinology, Diabetes & Metabolism healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1275614372.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Camilo Jimenez, M.D has received a total of $29,006 in payments from pharmaceutical and medical device companies, with $236.84 received in 2024. These payments were reported across 25 transactions from 6 companies. The most common payment nature is "Consulting Fee" ($16,332).
As a Medicare-enrolled provider, Jimenez has provided services to 639 Medicare beneficiaries, totaling 759 services with total Medicare billing of $62,458. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Houston, TX
- Active Since 10/17/2006
- Last Updated 02/13/2025
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1275614372
Products in Payments
- SOMAVERT (Drug) $14,619
- AZEDRA (Drug) $5,911
- Lysodren (Drug) $3,400
- MK-6482 (Drug) $1,875
- WELIREG (Drug) $1,688
- Tymlos (Biological) $13.54
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Houston
Dr. Rocio Harbison, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $1.1M
Endocrinology, Diabetes & Metabolism $1.1M
Dr. Andres Splenser, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $998,793
Endocrinology, Diabetes & Metabolism $998,793
Damaris Vega, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $995,666
Endocrinology, Diabetes & Metabolism $995,666
Rakesh Patel, Do, DO
Endocrinology, Diabetes & Metabolism — Payments: $435,758
Endocrinology, Diabetes & Metabolism $435,758
Dr. Steven Petak, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $388,893
Endocrinology, Diabetes & Metabolism $388,893
Dr. Veena Watwe, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $224,669
Endocrinology, Diabetes & Metabolism $224,669